SRNE - Sorrento achieves 100% discharge rate in COVI-MSC study in COVID-19

Sorrento Therapeutics (SRNE) has completed enrollment in its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respiratory failure ((ARD)) or acute respiratory distress syndrome ((ARDS)).This current study (MSC-COV-101) is a single arm study of the safety and preliminary efficacy of COVI-MSCs administered every other day for up to three infusions for a total of 1 x 106 cells/kg, with patients being followed for 28 days following the final infusion. A total of 10 patients were enrolled and all were discharged from the hospital to home within three days of their last COVI-MSC infusion. The study met its primary objective to demonstrate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS. Once the full dataset is available, Sorrento will be working with the FDA to plan a placebo-controlled study to support an emergency use authorization submission.SRNE

For further details see:

Sorrento achieves 100% discharge rate in COVI-MSC study in COVID-19